Icon Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 23 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
- Revenue Growth 17.85%
- Profit Growth 35.87%
- Ebitda 17.02%
- Net Worth 12.23%
- Total Assets -2.32%
About Icon Drugs
Icon Drugs Private Limited (IDPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 January 2002 and has a history of 23 years and one month. Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.50 M.
Sushrut Dange, Umesh Dange, and Rachana Dange serve as directors at the Company.
Company Details
-
Location
Nagpur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231MH2002PTC134479
-
Company No.
134479
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Jan 2002
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Icon Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sushrut Dange
|
Director | 27-Feb-2017 | Current |
|
Umesh Dange
|
Director | 08-Jan-2002 | Current |
|
Rachana Dange
|
Director | 15-Mar-2022 | Current |
Financial Performance of Icon Drugs.
Icon Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 17.85% increase. The company also saw a substantial improvement in profitability, with a 35.87% increase in profit. The company's net worth Soared by an impressive increase of 12.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Icon Drugs?
In 2023, Icon Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Medayu Healthcare LlpUmesh Dange is a mutual person
-
A.J. Grace Hospital Private Limited
Umesh Dange is a mutual person
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- Ing Vysya Bank Limited : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Nov 2010 | Ing Vysya Bank Limited | ₹2.50 M | Open |
How Many Employees Work at Icon Drugs?
Icon Drugs has a workforce of 13 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Icon Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Icon Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
